KCM
CYTK icon

Kennedy Capital Management’s Cytokinetics CYTK Stock Holding History

Kennedy Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
14,785
+424
+3% +$30.4K 0.02% 495
2026
Q1 		$947K Buy
14,361
+1,178
+9% +$74.9K 0.02% 492
2025
Q4 		$838K Buy
13,183
+162
+1% +$10.1K 0.02% 495
2025
Q3 		$716K Buy
13,021
+6,350
+95% +$262K 0.02% 519
2025
Q2 		$220K Buy
6,671
+165
+3% +$5.74K 0.01% 563
2025
Q1 		$261K Buy
6,506
+83
+1% +$3.81K 0.01% 614
2024
Q4 		$302K Buy
6,423
+1,172
+22% +$60.9K 0.01% 649
2024
Q3 		$277K Buy
5,251
+755
+17% +$42.1K 0.01% 663
2024
Q2 		$244K Buy
4,496
+1,304
+41% +$78.7K 0.01% 674
2024
Q1 		$224K Buy
+3,192
New +$247K ﹤0.01% 697
2015
Q4 		– Sell
-348,701
Closed -$2.33M – 735
2015
Q3 		$2.33M Buy
+348,701
New +$2.38M 0.05% 544

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's CYTK Position: Q2 2026 in Review

Kennedy Capital Management increased its Cytokinetics (CYTK) stake by 3% in Q2 2026, buying an estimated $30.4K and bringing the position to 14,785 shares worth $1.26M. The position accounts for 0.02% of the portfolio, ranked #495.

Kennedy Capital Management first reported a position in CYTK in Q3 2015 and has held it in 11 quarters since. The position peaked at $2.33M in Q3 2015. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Kennedy Capital Management held 14,785 shares of Cytokinetics worth $1.26M as of Q2 2026.
  • Kennedy Capital Management bought 424 Cytokinetics shares in Q2 2026, an estimated $30.4K.
  • Cytokinetics made up 0.02% of Kennedy Capital Management's portfolio in Q2 2026, its #495 holding.
  • Kennedy Capital Management first reported a position in Cytokinetics in Q3 2015 and has held it in 11 quarters since.
  • Kennedy Capital Management's Cytokinetics position peaked at $2.33M in Q3 2015.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.